201286-64-8

Usage

Uses

Used in Organic Synthesis:
3,5-Dimethylpyridine-4-carboxaldehyde is used as a key intermediate in the synthesis of various complex organic compounds. Its stability and reactivity make it a valuable component in the creation of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
3,5-Dimethylpyridine-4-carboxaldehyde is used as a building block in the development of new pharmaceutical compounds. Its properties, such as miscibility with water and its structure, contribute to its potential use in the formulation of drugs with improved efficacy and safety.
Used in Synthetic Chemistry:
3,5-Dimethylpyridine-4-carboxaldehyde is used as a versatile reagent in synthetic chemistry. Its ability to participate in various chemical reactions, such as condensation, reduction, and oxidation, allows for the synthesis of a wide range of chemical products with diverse applications.
It is important to handle 3,5-Dimethylpyridine-4-carboxaldehyde correctly to ensure safety, as with many chemicals, due to its potential hazards.

InChI:InChI=1/C8H9NO/c1-6-3-9-4-7(2)8(6)5-10/h3-5H,1-2H3

Upstream product

• 201286-65-9 4-bromo-3,5-dimethylpyridine 
• 591-22-0 3,5-Lutidine 
• 68-12-2 N,N-dimethyl-formamide 

Relevant academic research and scientific papers

Halogen Bonding Molecular Capsules

Molecular capsules based solely on the interaction of halogen bonding (XB) are presented along with their host-guest binding properties in solution. The first example of a well-defined four-point XB supramolecular system is realized by decorating resorcin[4]arene cavitands with polarized halogen atoms for dimerization with tetra(4-pyridyl) resorcin[4]arene cavitands. NMR binding data for the F, Cl, Br, and I cavitands as the XB donor show association constants (Ka) of up to 5370 M-1 (ΔG283 K=-4.85 kcal mol-1, for I), even in XB-competitive solvent, such as deuterated benzene/acetone/methanol (70:30:1) at 283 K, where comparable monodentate model systems show no association. The XB capsular geometry is evidenced by two-dimensional HOESY NMR, and the thermodynamic profile shows that capsule formation is enthalpically driven. Either 1,4-dioxane or 1,4-dithiane are encapsulated within each of the two separate cavities within the XB capsule, with of up to Ka=9.0 108 M-2 (ΔG283 K=-11.6 kcal mol-1).

TETRACYCLIC INHIBITORS OF JANUS KINASES

The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.